Floxuridine
- Generic Name
- Floxuridine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H11FN2O5
- CAS Number
- 50-91-9
- Unique Ingredient Identifier
- 039LU44I5M
- Background
An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gas...
- Indication
For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).
- Associated Conditions
- Stage 4 gastrointestinal adenocarcinoma
- Associated Therapies
- Palliative Treatment
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
- Conditions
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00008294
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 75
- Registration Number
- NCT00026234
- Locations
- 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States
Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 135
- Registration Number
- NCT00002716
- Locations
- 🇺🇸
CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
🇺🇸CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States
🇺🇸John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, United States
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 45
- Registration Number
- NCT00005049
- Locations
- 🇺🇸
NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York, New York, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004103
- Locations
- 🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT00002842
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT00001449
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT00001576
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.